Aducanumab, page-8

I love this end of the small cap world. These stocks are so under researched, us retail investors can really have an edge in price discovery in stocks like CGS. I've been listening to Brad OConnor's interviews in recent times and it's obvious that we'll see return to profitability in FY21. Of course, profit is not be all and end all situation but given how CGS invested heavily into their products from 2015 through to 2018 to have the suite of products ready and after decline in SP in 18/19, business model has improved significantly.

This is not without its risks but upside is great. We already had record high sales revenue in FY20 and expect more to come in FY21. Brad OConnor mentioned many times that when there is a treatment for Alzheimer's disease, it's fair to assume that demand for testing and monitoring of cognitive function will go up significantly.

I like to look at published articles on google scholar for Biotech companies to see how the field is adopting their technology. Just in the last 5 years, searching "Cogstate" in google scholar, you'll get 377 hits in 2016, 559 hits in 2017, 769 hits in 2018, 905 hits in 2019. So far in 2020, there's 629 hits with still 4.5 months left to go. That shows how the field of cognitive testing is adopting cogstate's technology. It'll have network effect which means the more studies that use cogstate to measure cognitive function, even more studies are going to use the same technology.

Whether we get the first ever FDA approved drug for treatment of Alzheimer's disease or not, future is bright. There are studies coming out as of late that Covid-19 causes mild brain damage. Common damage in areas responsible for smell but also in cognitive areas. It wouldn't surprise me when this pandemic slows down, many researchers will want to conduct studies on that theory. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30228-5/fulltext

Sorry this is bit of a rant. Apologies for spelling/grammar mistakes as i'm on mobile